MA33581B1 - Composition pharmaceutique contenant un dérivé de quinoléine - Google Patents

Composition pharmaceutique contenant un dérivé de quinoléine

Info

Publication number
MA33581B1
MA33581B1 MA34683A MA34683A MA33581B1 MA 33581 B1 MA33581 B1 MA 33581B1 MA 34683 A MA34683 A MA 34683A MA 34683 A MA34683 A MA 34683A MA 33581 B1 MA33581 B1 MA 33581B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
composition containing
quinoline derivative
formula
hydrogen atom
Prior art date
Application number
MA34683A
Other languages
Arabic (ar)
English (en)
Inventor
Masashi Bando
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33581(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA33581B1 publication Critical patent/MA33581B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui contient : un composé représenté par la formule (i), un sel pharmacologiquement acceptable de celui-ci, ou un solvate du composé ou un sel ; et une substance basique. La composition pharmaceutique a une excellente aptitude à la dissolution, est stable même après une conservation à long terme, et est utile en tant qu'agent prophylactique/thérapeutique pour des tumeurs. (dans la formule, r1 représente un atome d'hydrogène, un groupe alkyle en c1-6 ou un groupe cycloalkyle en c3-8 ; et r2 représente un atome d'hydrogène ou un groupe méthoxy.)
MA34683A 2009-08-19 2012-03-12 Composition pharmaceutique contenant un dérivé de quinoléine MA33581B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009190145 2009-08-19
PCT/JP2010/063804 WO2011021597A1 (fr) 2009-08-19 2010-08-16 Composition pharmaceutique contenant un dérivé de quinoléine

Publications (1)

Publication Number Publication Date
MA33581B1 true MA33581B1 (fr) 2012-09-01

Family

ID=43607048

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34683A MA33581B1 (fr) 2009-08-19 2012-03-12 Composition pharmaceutique contenant un dérivé de quinoléine

Country Status (32)

Country Link
US (3) US20120077842A1 (fr)
EP (1) EP2468281B1 (fr)
JP (1) JP5048871B2 (fr)
KR (1) KR101496395B1 (fr)
CN (1) CN102470133B (fr)
AU (1) AU2010285740C1 (fr)
BR (1) BR112012003592B8 (fr)
CA (1) CA2771403C (fr)
CL (1) CL2012000412A1 (fr)
CO (1) CO6440512A2 (fr)
CY (1) CY1117481T1 (fr)
DK (1) DK2468281T3 (fr)
ES (1) ES2564797T3 (fr)
HK (2) HK1167607A1 (fr)
HR (1) HRP20160283T1 (fr)
HU (1) HUE026957T2 (fr)
IL (1) IL217197A (fr)
MA (1) MA33581B1 (fr)
ME (1) ME02359B (fr)
MX (2) MX344927B (fr)
MY (1) MY162940A (fr)
NZ (1) NZ598291A (fr)
PE (1) PE20121030A1 (fr)
PL (1) PL2468281T3 (fr)
RS (1) RS54686B1 (fr)
RU (1) RU2548673C3 (fr)
SG (1) SG178009A1 (fr)
SI (1) SI2468281T1 (fr)
SM (1) SMT201600077B (fr)
UA (1) UA105671C2 (fr)
WO (1) WO2011021597A1 (fr)
ZA (1) ZA201108697B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
EP1925676A4 (fr) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
CA2620594C (fr) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Composition pharmaceutique dotee d'une meilleure capacite a se desintegrer
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (fr) * 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
CN101848895B (zh) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
WO2012166899A2 (fr) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
CN106139156B (zh) * 2014-11-14 2019-01-29 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
PL3263106T3 (pl) * 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN106075456A (zh) * 2015-04-27 2016-11-09 南京圣和药业股份有限公司 一种含乐伐替尼的药物组合物及其应用
US10246418B2 (en) * 2015-05-21 2019-04-02 Crystal Pharmatech Co., Ltd. Crystal form of lenvatinib methanesulfonate salt and preparation method thereof
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CN106999483B (zh) * 2015-08-17 2019-05-03 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
CZ2016240A3 (cs) 2016-04-27 2017-11-08 Zentiva, K.S. Soli lenvatinibu
EP3384901A1 (fr) 2017-04-04 2018-10-10 Synthon B.V. Composition pharmaceutique contenant du lenvatinib mesylate
US10583133B2 (en) 2018-03-12 2020-03-10 Shilpa Medicare Limited Pharmaceutical compositions of lenvatinib
CN110404079B (zh) * 2018-04-27 2023-01-24 北京睿创康泰医药研究院有限公司 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物
MX2021003862A (es) 2018-10-04 2021-05-27 Synthon Bv Formas cristalinas y procesos de besilato de lenvatinib.
PT3632436T (pt) 2018-10-04 2022-07-22 Synthon Bv Composição farmacêutica compreendendo sais de lenvatinib
CN113087666B (zh) * 2020-01-09 2021-12-14 南京正大天晴制药有限公司 无定形喹啉甲酰胺衍生物的制备方法
WO2021185006A1 (fr) * 2020-03-18 2021-09-23 上海博志研新药物技术有限公司 Composition pharmaceutique de lenvatinib, son procédé de préparation et son application
EP4147689A1 (fr) 2021-09-13 2023-03-15 Lotus Pharmaceutical Co., Ltd. Formulation de lenvatinib
CN114306271B (zh) * 2021-11-24 2023-04-07 石药集团中奇制药技术（石家庄）有限公司 一种仑伐替尼组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458148A (en) * 1974-04-19 1976-12-08 Wyeth John & Brother Ltd Carbocyclic-fused ring quinoline derivatives
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
ES2534713T3 (es) * 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
JP2006511486A (ja) * 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
US7994159B2 (en) * 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
CA2543650C (fr) * 2003-12-25 2010-10-26 Eisai Co., Ltd. Crystaux de sel de 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide ou de ses solvate, et leur procede de production
US8969379B2 (en) * 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
CN101233111A (zh) * 2005-06-23 2008-07-30 卫材R&D管理有限公司 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
US7550483B2 (en) * 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2753844A1 (fr) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions et procedes pour des therapies de la mucosite et d'oncologie

Also Published As

Publication number Publication date
HK1169599A1 (zh) 2013-02-01
CA2771403C (fr) 2015-02-24
AU2010285740C1 (en) 2016-03-17
CY1117481T1 (el) 2017-04-26
RU2548673C3 (ru) 2018-07-20
BR112012003592B8 (pt) 2021-05-25
RU2548673C2 (ru) 2015-04-20
KR101496395B1 (ko) 2015-02-26
KR20120055559A (ko) 2012-05-31
HRP20160283T1 (hr) 2016-05-06
NZ598291A (en) 2013-02-22
AU2010285740B2 (en) 2014-12-04
BR112012003592B1 (pt) 2020-11-03
UA105671C2 (uk) 2014-06-10
HK1167607A1 (en) 2012-12-07
CN102470133B (zh) 2013-08-28
EP2468281A1 (fr) 2012-06-27
MX2012002011A (es) 2012-03-26
JPWO2011021597A1 (ja) 2013-01-24
IL217197A0 (en) 2012-02-29
ME02359B (fr) 2016-06-20
MX344927B (es) 2017-01-11
AU2010285740A1 (en) 2011-12-15
US20120077842A1 (en) 2012-03-29
HUE026957T2 (en) 2016-07-28
CA2771403A1 (fr) 2011-02-24
PL2468281T3 (pl) 2016-06-30
SG178009A1 (en) 2012-03-29
US20210228722A1 (en) 2021-07-29
SI2468281T1 (sl) 2016-05-31
MY162940A (en) 2017-07-31
RS54686B1 (en) 2016-08-31
CN102470133A (zh) 2012-05-23
EP2468281B1 (fr) 2016-01-27
SMT201600077B (it) 2016-04-29
PE20121030A1 (es) 2012-08-18
ZA201108697B (en) 2012-07-25
ES2564797T3 (es) 2016-03-29
IL217197A (en) 2016-08-31
RU2012103471A (ru) 2013-09-27
WO2011021597A1 (fr) 2011-02-24
DK2468281T3 (en) 2016-03-21
US20130296365A1 (en) 2013-11-07
CO6440512A2 (es) 2012-05-15
BR112012003592A2 (pt) 2016-03-15
CL2012000412A1 (es) 2012-08-31
EP2468281A4 (fr) 2013-01-23
JP5048871B2 (ja) 2012-10-17

Similar Documents

Publication Publication Date Title
MA33581B1 (fr) Composition pharmaceutique contenant un dérivé de quinoléine
MA30890B1 (fr) Compose indole
MA33072B1 (fr) Composes pyridazinone
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
AR051780A1 (es) Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
RU2018121834A (ru) Новое соединение бифенила или его соль
TW200607504A (en) Cinnamide compound
MA32164B1 (fr) Derive heterocyclique fusionne et son utilisation
MA32171B1 (fr) Compose heterocyclique
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA33851B1 (fr) Compose heterocyclique contenant de l'azote et fongicide agricole
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MA29323B1 (fr) Composes de l'acide pyridylacetique
CO6190582A2 (es) Derivados de heteroarilamida
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR083760A1 (es) Agentes antibacterianos y composiciones farmaceuticas
MA32642B1 (fr) Amides utiles en therapie
AR094123A1 (es) Compuesto triciclicos
MA33352B1 (fr) Derives de cyclopenta[c]pyrrolylalkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
JP2018517693A (ja) 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA31784B1 (fr) Nouveaux dérivés d'imidazole
EA201100476A1 (ru) Агонист глюкокортикоидного рецептора, содержащий новые производные 1,2,3,4-тетрагидрохиноксалина с фенильной группой, имеющей структуру эфира сульфоновой кислоты, введенной в нее в качестве заместителя